Ozempic Alternatives & Comparison
Ozempic (semaglutide) set beside Mounjaro, Trulicity, Rybelsus: how each works, what its trials measured, what it costs, and who sells it.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
These are the drugs people weigh against Ozempic. The Ozempic drug guide covers Ozempic itself, the Ozempic cost page covers its price, and the Ozempic how-to-get page covers the routes to a prescription.
Ozempic Alternatives Compared
Acts on GIP as well as GLP-1, and often moves A1c and weight further
Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon.
Neither drug carries a weight-loss label. Both treat type 2 diabetes, and both get prescribed off-label for weight constantly. SURPASS-2 compared them directly: −11.2 kg on Mounjaro 15 mg against −5.7 kg on Ozempic 1 mg over 40 weeks, with a larger A1C drop too. Ozempic has SUSTAIN-6 (MACE −26%). Mounjaro now has SURPASS-CVOT (NEJM, December 2025), in which it was noninferior to dulaglutide, and its label carries a cardiovascular indication too. Ozempic lists at about $1,028 and now has a $349–$499 NovoCare self-pay price; LillyDirect lists Mounjaro at $499 a month at every strength.
Full Mounjaro vs Ozempic comparison →Another weekly GLP-1, backed by a long real-world track record
Dulaglutide is a long-acting GLP-1 receptor agonist engineered by fusing two modified GLP-1 peptide chains to a human IgG4 Fc fragment, which extends the half-life to about five days and allows once-weekly dosing.
Both are weekly GLP-1s for type 2 diabetes, and Ozempic is the stronger on both endpoints people ask about: −6.5 kg against Trulicity's −3.0 kg, and MACE −26% in SUSTAIN-6 against −12% in REWIND. One caveat cuts the other way. REWIND enrolled a majority who had not yet had a cardiovascular event, which is a harder population in which to show benefit. List prices are close, about $1,028 for Ozempic and $1,007 for Trulicity, with savings cards limited to commercial insurance. Both also sell direct for cash: Ozempic at $349–$499 through NovoCare and Trulicity at $389 through LillyDirect.
Full Trulicity vs Ozempic comparison →The same molecule as a daily tablet, for anyone ruling out injections. In the US it is now sold as Ozempic tablets, which replace Rybelsus
Rybelsus delivers semaglutide — a GLP-1 receptor agonist — in tablet form by co-formulating each pill with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that transiently raises gastric pH and helps the semaglutide peptide cross the gastric mucosa intact before stomach acid and proteases can degrade it.
The molecule is the same, and the route is the difference. Ozempic is injected once a week. Rybelsus is swallowed once a day before breakfast, with nothing else for half an hour, because the SNAC absorption enhancer works only when the stomach is empty. In the US, Rybelsus is being discontinued: on June 4, 2026 the FDA listed all three strengths as discontinued, to be replaced by Ozempic tablets, the same semaglutide reformulated at 1.5, 4 and 9 mg and on sale since May 4, 2026. Under the shared label, 7 mg of Rybelsus corresponds to 4 mg of Ozempic tablets and 14 mg to 9 mg, and the label says the two are not substitutable milligram for milligram. On heart outcomes, SUSTAIN-6 found the injection superior to placebo for major cardiovascular events (HR 0.74). For the tablet, PIONEER 6 showed noninferiority (HR 0.79) and the later SOUL trial showed superiority (HR 0.86), which added a cardiovascular indication to the tablet label. The Ozempic pen costs $349 to $499 a month through NovoCare self-pay, and Ozempic tablets $149 to $299 by strength. The choice is between a daily tablet routine and a weekly injection.
Full Rybelsus vs Ozempic comparison →Same molecule at a higher maintenance dose, approved for weight management rather than diabetes
Wegovy mimics the GLP-1 hormone to signal fullness to the brain, slow stomach emptying, and reduce overall caloric intake.
Both are semaglutide from the same manufacturer, with different target doses and different labels. Wegovy's usual weight-management dose is 2.4 mg, with a 7.2 mg maximum for some adults; Ozempic tops out at 2 mg for diabetes. Each has its own cardiovascular result in its own population: SELECT's MACE −20% in obesity without diabetes, and SUSTAIN-6's −26% in diabetes at high risk. Both have NovoCare self-pay prices: $349 a month for Wegovy and $349–$499 for Ozempic. Which one you can get is usually decided by which diagnosis is on the prescription.
Full Wegovy vs Ozempic comparison →Drug facts on this page were last verified against each drug's FDA label and trial record.
Compare compounded Semaglutide providers
Compounded semaglutide sits at a middle figure of $199/month across 726 price points in the register, spanning $49 to $599. The partners below are ordered by our partner economics.
Compare compounded Tirzepatide providers
Compounded tirzepatide sits at a middle figure of $250/month across 697 price points in the register, spanning $69 to $849. The partners below are ordered by our partner economics.
Compare every Ozempic provider
Current price, verification status, product form and the states each seller ships to, all on one screen.